CCND1 and neoplasm: In a retrospective study carried out at four French institutions, patients with recurrent and/or metastatic HNSCC experienced accelerated tumor growth and had shorter PFS after anti-PD-1 and anti-PD-L1 treatment, with three of the patients harboring a CCND1 amplification (27).